Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 18.

Journal Article

Bloch, W., Baumann, F., Zimmer, P., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Tesch, H., Schuetz, F., Lueftner, D. and Jackisch, C. (2016). Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER plus women - Results of the 3rd interim analysis of BRAWO. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Link, T., Blohmer, J-U., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Schmitt, W. D., Jackisch, C., Rhiem, K. E., Hanusch, C., Denkert, C., Sinn, B. V., Engels, K., Nekljudova, V. and Loibl, S. (2020). GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Ann. Oncol., 31. S. S308 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Lueftner, D., Grischke, E. M., Fasching, P., Decker, T., Schneeweiss, A., Uleer, C., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Schuetz, F. and Jackisch, C. (2015). Disease characteristics of subgroup patients treated with everolimus plus exemestane for < 12 months, >= 12 to < 18months, and >= 18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. Eur. J. Cancer, 51. S. S288 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Marme, F., Schneeweiss, A., Aigner, J., Eidt, S., Altevogt, P., Sinn, P. and Wirtz, R. M. (2012). Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Moebus, V., Diel, I. J., Harbeck, N., Elling, D., Jackisch, C., Thomssen, C., Untch, M., Conrad, B., Schneeweiss, A., Kreienberg, R., Huober, J., Mueller, V., Lueck, H-J, Bauerfeind, I., Loibl, S., Nekljudova, V. and von Minckwitz, G. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer 1st Interim Efficacy Analysis. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P. A., Solbach, C., Huober, J., Rhiem, K. E., Nekljudova, V., Luebbe, K. and Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). Ann. Oncol., 31. S. S303 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Schuetz, F., Grischke, E-M, Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Jackisch, C., Idiftner, D. and Fasching, P. A. (2016). Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Tesch, H., Grischke, E-M, Fasching, P., Decker, T., Uleer, C., Schneeweiss, A., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F. and Lueftner, D. (2015). Results of the 3rd interim analysis of BRAWO - breast cancer treatment with everolimus and exemestane for ER plus women. Oncol. Res. Treat., 38. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Tesch, H., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F. and Lueftner, D. (2016). Results of the 3rd interim analysis of the non-interventional trial BRAWO - Subanalysis of patients < 70 years and >= 70 years. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Thewes, V., Simon, R., Hlevnjak, M., Schlotter, M., Schroeter, P., Schmidt, K., Wu, Y., Anzeneder, T., Wang, W., Windisch, P., Kirchgaessner, M., Melling, N., Kneisel, N., Buettner, R., Deuschle, U., Sinn, H. P., Schneeweiss, A., Heck, S., Kaulfuss, S., Hess-Stumpp, H., Okun, J. G., Sauter, G., Lykkesfeldt, A. E., Zapatka, M., Radlwimmer, B., Lichter, P. and Toenjes, M. (2017). The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER alpha-negative breast cancer. Oncogene, 36 (29). S. 4124 - 4135. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5594

Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Wirtz, R. M., Aigner, J., Marme, F., Eidt, S., Altevogt, P., Sinn, P. and Schneeweiss, A. (2013). High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Wirtz, R. M., Scheffen, I., Marme, F., Laible, M., Sclombs, K., Schumacher, C., Schneeweiss, A., Eidt, S. and Sinn, H-P (2017). Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

This list was generated on Tue Oct 26 01:50:15 2021 CEST.